Correlation of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging and Tumor Histopathology in Patients With Infiltrating Gliomas

Trial ID: NCT04772456

Interventional - Phase 1 - Recruiting

The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).

Conditions

• Glioma

Interventions

• Hyperpolarized 13C-Pyruvate

Eligibility

Inclusion criteria

• • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection.
• Ages 18-80, including male and female
• Suitable to undergo contrast-enhanced MRI
• Negative serum pregnancy test

Exclusion criteria

• Inability to undergo MRI scan
• Inability to receive IV contrast secondary to severe reaction or renal insufficiency.

Sponsor

University of Maryland, Baltimore

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows